128TiP A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)

医学 贝伐单抗 结直肠癌 内科学 临床研究阶段 肿瘤科 癌症研究 癌症 化疗
作者
Ren Lin,Sihai Zhao,Liang Su,Yong Sang Hong,Jie Luo,Wang Yongmei,Sihai Dave Zhao
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1519-S1519
标识
DOI:10.1016/j.annonc.2023.10.263
摘要

Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in patients with MSS mCRC and pMMR. A recent trial of botensilimab (next-generation anti–CTLA-4 antibody) + balstilimab (anti-PD-1 antibody) for heavily pretreated pMMR/MSS mCRC reported promising results. Cadonilimab is a humanized bi-specific antibody that targets both PD-1 and CTLA-4. Its higher binding avidity in a tumor-like setting and Fc-null design may increase drug retention in tumors and improve safety. A more intensive chemotherapy, FOLFOXIRI + bevacizumab, can enhance the antitumor effect of ICI by increasing tumor immunogenicity. AtezoTRIBE, a phase II study, showed that adding atezolizumab to first-line FOLFOXIRI + bevacizumab might improve progression-free survival (PFS) in patients with mCRC. Therefore, in this study we aim to investigate the efficacy and safety of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for patients with unresectable pMMR/MSS mCRC. This is a multicenter single arm phase II study. Eligibility criteria include: histologically or cytologically confirmed pMMR/MSS mCRC; age 18-75 years; naive to systemic treatment in the metastatic setting; at least 1 measurable lesion according to RECIST 1.1; ECOG PS 0-1; and adequate organ function. Patients with high microsatellite instability (MSI-H) tumors and those who previously received immunotherapy are excluded. Twenty eligible participants will receive FOLFOXIRI (intravenous [i.v.] irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 48-h infusion) + bevacizumab 5 mg/kg i.v. and cadonilimab 6 mg/kg i.v. Treatment is administered for up to twelve 14-day cycles followed by maintenance with fluorouracil and leucovorin (or capecitabine) + bevacizumab and cadonilimab for a total of 52 weeks or until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint is objective response rate per RECIST 1.1. Secondary endpoints are PFS, overall survival, and safety. Enrollment is ongoing. NCT05839470. The authors. Akeso, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老大蒂亚戈应助YJ888采纳,获得10
1秒前
JamesPei应助潇湘雪月采纳,获得10
1秒前
bbczj发布了新的文献求助10
3秒前
4秒前
5秒前
南风知我意完成签到,获得积分20
6秒前
段一帆发布了新的文献求助30
8秒前
wangqinlei完成签到 ,获得积分10
8秒前
fenghp发布了新的文献求助10
9秒前
王馨雨发布了新的文献求助10
9秒前
11秒前
CipherSage应助ccalvintan采纳,获得10
12秒前
12秒前
雪天的阳完成签到 ,获得积分10
14秒前
15秒前
16秒前
16秒前
烟花应助ren采纳,获得10
17秒前
讨厌科研发布了新的文献求助10
17秒前
量子星尘发布了新的文献求助10
18秒前
苏卿应助科研通管家采纳,获得30
19秒前
fd163c应助科研通管家采纳,获得10
20秒前
香蕉觅云应助科研通管家采纳,获得10
20秒前
思源应助科研通管家采纳,获得10
20秒前
SYLH应助科研通管家采纳,获得10
20秒前
20秒前
CAOHOU应助科研通管家采纳,获得10
20秒前
爆米花应助科研通管家采纳,获得10
20秒前
SYLH应助科研通管家采纳,获得30
20秒前
小蘑菇应助科研通管家采纳,获得10
20秒前
20秒前
殷勤的紫槐完成签到,获得积分10
20秒前
风轻青柠发布了新的文献求助10
21秒前
21秒前
机智冬灵完成签到,获得积分10
22秒前
23秒前
为小嗳打伞完成签到 ,获得积分10
25秒前
小木安华发布了新的文献求助10
25秒前
体贴的之卉完成签到,获得积分20
27秒前
大侠完成签到 ,获得积分10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174